Limited value of myeloablative therapy for late multiple myeloma
作者： R Alexanian , M Dimopoulos , T Smith , K Delasalle , B Barlogie
DOI: 10.1182/BLOOD.V83.2.512.512
关键词: Multiple myeloma 、 Bone marrow 、 Internal medicine 、 Progenitor cell 、 Oncology 、 Melphalan 、 Medicine 、 Dexamethasone 、 Stem cell 、 Surgery 、 Chemotherapy 、 Immunopathology
摘要: The utility of myeloablative therapy supported by autologous bone marrow (BM) or blood progenitor cells was assessed in 49 patients with multiple myeloma who had received at least 1 year prior chemotherapy. Outcomes were compared those similar did not receive intensive treatment primarily for socioeconomic reasons. Among disease resistant relapse despite vincristine-doxorubicin continuous infusion pulse dexamethasone (VAD), a 61% response rate associated median remission time 5 months. After primary resistance more than year, 6 15 responded and the overall survival to that control patients. For melphalan- VAD, Current treatments BM stem useful very few after first
ashpublications.org
sci-hub.se 参考文章(14)
B Barlogie, R Alexanian, KA Dicke, G Zagars, G Spitzer, S Jagannath, L Horwitz, High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma Blood. ,vol. 70, pp. 869- 872 ,(1987) , 10.1182/BLOOD.V70.3.869.869
B Barlogie, R Alexanian, D Dixon, L Smith, L Smallwood, K Delasalle, Prognostic implications of tumor cell DNA and RNA content in multiple myeloma Blood. ,vol. 66, pp. 338- 341 ,(1985) , 10.1182/BLOOD.V66.2.338.338
B Drewinko, R Alexanian, H Boyer, B Barlogie, SI Rubinow, The growth fraction of human myeloma cells Blood. ,vol. 57, pp. 333- 338 ,(1981) , 10.1182/BLOOD.V57.2.333.333
MA Dimopoulos, R Alexanian, D Przepiorka, J Hester, B Andersson, S Giralt, R Mehra, K van Besien, KB Delasalle, C Reading, Thiotepa, Busulfan, and Cyclophosphamide: A New Preparative Regimen for Autologous Marrow or Blood Stem Cell Transplantation in High-Risk Multiple Myeloma Blood. ,vol. 82, pp. 2324- 2328 ,(1993) , 10.1182/BLOOD.V82.8.2324.2324
Meletios A Dimopoulos, Bart Barlogie, Terry L Smith, Raymond Alexanian, High Serum Lactate Dehydrogenase Level as a Marker for Drug Resistance and Short Survival in Multiple Myeloma Annals of Internal Medicine. ,vol. 115, pp. 931- 935 ,(1991) , 10.7326/0003-4819-115-12-931
Raymond Alexanian, Bart Barlogie, Jordan Gutterman, Alpha-interferon combination therapy of resistant myeloma. American Journal of Clinical Oncology. ,vol. 14, pp. 188- 192 ,(1991) , 10.1097/00000421-199106000-00003
Brian G. M. Durie, Sydney E. Salmon, A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer. ,vol. 36, pp. 842- 854 ,(1975) , 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U
Meletios A. Dimopoulos, Kay B. Delasalle, Richard Champlin, Raymond Alexanian, Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma British Journal of Haematology. ,vol. 83, pp. 240- 244 ,(1993) , 10.1111/J.1365-2141.1993.TB08278.X
T Takahashi, B Lim, N Jamal, D Tritchler, G Lockwood, S McKinney, D E Bergsagel, H A Messner, Colony growth and self renewal of plasma cell precursors in multiple myeloma. Journal of Clinical Oncology. ,vol. 3, pp. 1613- 1623 ,(1985) , 10.1200/JCO.1985.3.12.1613
P McLaughlin, R Alexanian, Myeloma protein kinetics following chemotherapy. Blood. ,vol. 60, pp. 851- 855 ,(1982) , 10.1182/BLOOD.V60.4.851.851